The University of Massachusetts Memorial Medical Center in Worcester is now enrolling patients in BrainStorm Cell Therapeutics' (BCLI +0.8%) Phase 2 clinical trial evaluating the safety and efficacy of NurOwn in ALS patients. The medical center is the second of three sites participating in the 48-patient trial. Mass General started in June and the Mayo Clinic will come on line in Q3.
NurOwn is an autologous adult stem cell therapy that differentiates bone marrow-derived mesenchymal stem cells (MSC) into specialized neuron-supporting cells.
The study's primary endpoint is the safety of intrathecal and intramuscular injections of NurOwn. Secondary endpoints are efficacy-related (change in slow vital capacity and change in ALS Functional Rating Scale).
Related ticker: (CUR -3.2%)